Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

TaiGen Biotech's Novel Antibiotic Approved for Use in China

publication date: Jun 14, 2016
TaiGen Biotech, a Taiwan company with a Beijing subsidiary, received CFDA approval to market a novel antibiotic, Taigexyn® (nemonoxacin), in mainland China. The antibiotic showed activity against drug-resistant bacterial strains. TaiGen said Taigexyn is the first Class 1.1 new drug developed by a Taiwanese company approved for China use and also the first new drug approved after the CFDA required companies to self-inspect clinical trial data in July 2015. In China, Taigexyn will be marketed by Zhejiang Medicine, which in-licensed rights to the antibiotic for $8 million upfront plus royalties and sales milestones. More details....

Stock Symbol: (TWO: 4157)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital